High potency immunogenic zika virus compositions
US10273269B2 · kind B2 · utility
79Cited by
23References
28Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 10, 2018 |
| Grant date | Apr 30, 2019 |
| Priority date | — |
| Expiry date | Jul 10, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein, in some embodiments, are Zika Virus immunogenic compositions that include a cationic lipid nanoparticle (LNP) encapsulating messenger ribonucleic acid (mRNA) having an open reading frame encoding Zika Virus antigens, a pan HLA DR-binding epitope (PADRE), and a 5′ terminal cap modified to increase mRNA translation efficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.